Roche sells three drugs to Actavis

Roche has agreed to sell three of its products to the Iceland-based generics company Actavis Group. The deal covers the cardiovascular drugs Bezalip and Rapilysin and dermatology med Neotigason, with combined 2006 sales of $117.3 million. Roche will continue to sell the remedies in Latin America under license from Actavis. The deal is part of Roche's strategy of retrenching to its core products. It's expected to close around year's end.

- check out this release for more

Suggested Articles

Merck KGaA has big plans for a site in Switzerland where it intends to knit together biologics development and manufacturing. 

Biocon’s key biosimilars plant in Bengaluru, India, has gotten mixed reviews from the FDA and has now received a Form 483 with five observations.

Eli Lilly and Incyte are investing heavily in JAK inhibitor Olumiant's chances in atopic dermatitis, but does it stand a chance against Dupixent?